Condition: Melanoma · Non Small Cell Lung Cancer · Cervical Carcinoma · Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd.
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.
This description comes directly from the study's public registry record.
Xu Wen · 13260921233 · zhuce@lanmabio.com
Always discuss trial participation with your own doctor first.
| Tianjin Beichen Hospital | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05366478